医药行业周报：从TEMPUS出发，看AI赋能基因检测领域

Investment Rating - The report maintains a "Recommended" rating for the pharmaceutical and biotechnology industry [1] Core Insights - The pharmaceutical sector outperformed the CSI 300 index, with a weekly increase of 2.63% compared to the index's 1.19% [3][5] - AI is expected to empower the medical field, particularly in gene testing, with companies like Tempus leading the way in data analysis and AI optimization for cancer diagnosis and treatment [15][17] - The report emphasizes the importance of high-quality data in the AI medical field, which is a key competitive advantage [17] Summary by Sections 1. Weekly Pharmaceutical Sector Performance - The pharmaceutical sector's performance was characterized by a 2.63% increase, while the CSI 300 index rose by 1.19% during the week of February 10-14, 2025 [3][5] - Year-to-date, the pharmaceutical sector has seen a decline of 11.13%, underperforming the CSI 300 index by 25.93 percentage points [5] 2. Industry Events/Policy Overview - The report highlights the announcement of 274 exemplary projects in the 5G+ healthcare application pilot program, which aims to promote the large-scale development of 5G healthcare applications [13] 3. Industry Investment Strategy - The report suggests prioritizing investments in companies with quality data access and a broad user base, particularly in imaging, gene testing, pathology, robotics, and health management sectors [18] - It notes that the pharmaceutical industry is currently at a historical low, presenting investment opportunities in 2025, especially in innovative drugs and medical devices [19][20] 4. Recommended Stocks - Key recommended stocks include: - Hengrui Medicine: Expected to see growth from innovative drugs and international expansion [29] - Baiyue Pharmaceutical: Leading in innovative drug development with strong sales growth [28] - Wuxi AppTec: A global leader in integrated CXO services with strong order growth [31] - Aibo Medical: High growth potential in the ophthalmic device sector [32] 5. Market Outlook - The report anticipates a recovery in the pharmaceutical sector in 2025, driven by improved fundamentals and a favorable macroeconomic environment [20][21] - It highlights the potential for innovative drugs and medical devices to benefit from policy support and internationalization efforts [21][24]